Selection of treatment regimens for pancreatic duct stones: A comparative analysis

Jinbin DONG; Weibing FANG; Yihai SHI

doi:10.3969/j.issn.1001-5256.2022.11.023

Volume 38 Issue 11

Nov. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(11): 2558-2564

PDF( 2050 KB)

Selection of treatment regimens for pancreatic duct stones: A comparative analysis

DOI: 10.3969/j.issn.1001-5256.2022.11.023

1.
Department of Gastroenterology, Gongli Hospital Affiliated to Naval Medical University, Shanghai 200135, China
2.
Department of Medical Ultrasonics, Chizhou Second Hospital, Chizhou, Anhui 247100, China

Research funding:

Shanghai Pudong New Area Health and Family Planning Commission Key Subspecialty Program (PWZy2020-05);

Medical Discipline Construction Project of Pudong Health Commiittee of Shanghai (PWYgf2021-08)

More Information

Corresponding author: SHI Yihai, zhuanyongabc@yeah.net(ORCID: 0000-0001-8489-4811)
Received Date: 2022-04-11
Accepted Date: 2022-05-12
Published Date: 2022-11-20

Abstract

Abstract

Objective To investigate the clinical efficacy of endoscopic retrograde cholangiopancreatography (ERCP), laparoscopy, and laparotomy in the treatment of pancreatic duct stones (PDS) by collecting related clinical data, to summarize the experience in selecting treatment regimens for PDS, and to further explore feasible treatment regimens that could maximize and optimize the benefits of PDS patients. Methods A retrospective analysis was performed for the clinical data of 131 PDS patients who were treated in Gongli Hospital Affiliated to Naval Medical University from June 2014 to December 2018, and according to the surgical procedure, they were divided into ERCP group with 69 patients, laparoscopy group with 32 patients, and laparotomy group with 30 patients. Related indices were monitored before and after treatment, and surgical outcome was compared between the laparoscopy group and the laparotomy group. The independent samples t-test was used for comparison of normally distributed continuous data between two groups; a one-way analysis of variance was used for comparison between multiple groups, and the least significant difference t-test or the SNK-q test was used for further comparison between two groups. The Mann-Whitney U test was used for comparison of continuous data with skewed distribution between two groups, and the Kruskal-Wallis H test was used for comparison between multiple groups. An repeated measures analysis of variance and the Friedman test were used for comparison of related indices before and after surgery, and the chi-square test was used for comparison of categorical data between groups. Results Among the 131 PDS patients, there were 40 patients with type Ⅰ PDS, 76 with type Ⅱ PDS, and 15 with type Ⅲ PDS. There was no significant difference in the distribution of main surgical methods between the laparoscopy group and the laparotomy group (χ²=1.93, P > 0.05). There were significant differences between the laparoscopy group and the laparotomy group in the dynamic changes of white blood cell count, C-reactive protein, procalcitonin, and Homeostasis Model Assessment of Insulin Resistance after surgery (F=24.68, χ²=227.66, F=45.37, F=106.71, all P < 0.05). Compared with the laparotomy group, the laparoscopy group had significantly shorter time of operation, significantly lower intraoperative blood loss, significantly shorter time to first flatus after surgery, a significantly lower frequency of use of pain-relieving drugs, shorter time to extraction of abdominal drainage tube, lower incidence rates of short-term postoperative complications, and a significantly shorter length of postoperative hospital stay (t=-4.80, t=-9.43, Z=-6.78, t=-11.59, Z=-6.77, χ²=9.24, t=-3.60, all P < 0.05). The incidence rate of short-term postoperative complications was 24.64% in the ERCP group, 28.13% in the laparoscopy group, and 66.67% in the laparotomy group, with a significant difference between groups (χ²=17.12, P < 0.05), and the ERCP group and the laparoscopy group had a significantly lower incidence rate of short-term postoperative complications than the laparotomy group (χ²=15.78 and 9.24, P < 0.05 and P=0.02). The treatment response rate was 91.30% in the ERCP group, 93.75% in the laparoscopy group, and 73.33% in the laparotomy group, with a significant difference between the three groups (χ²=7.70, P=0.02), and the ERCP group and the laparoscopy group had a significantly better response rate than the laparotomy group (χ²=5.56 and 4.77, P=0.02 and 0.03). Conclusion ERCP is the preferred method for minimally invasive treatment of some patients with type Ⅰ/Ⅱ PDS and is safe and effective with few serious complications. Surgical operation is an important method for the treatment of complex PDS, but with complicated techniques and difficult operation. Compared with laparotomy, laparoscopy has the advantages of small trauma, few serious complications, and high abdominal pain remission rate and can significantly shorten the time of operation, reduce intraoperative blood loss, and shorten the length of postoperative hospital stay. Therefore, laparoscopy should be the preferred regimen for the treatment of complex PDS.
- Pancreatic Duct Stones,
- Cholangiopancreatography, Endoscopic Retrograde,
- Laparoscopy,
- Digestive System Surgical Procedures

FullText(HTML)

References(16)

References

[1]	XU ZR, WANG HZ, YANG ZQ, et al. Risk factors analysis of pancreatic ductal stones combined with malignant tumor beside stones[J]. Chin J Dig Surg, 2018, 17(12): 1204-1208. DOI: 10.3760/cma.j.issn.1673-9752.2018.12.011. 徐正荣, 王槐志, 杨智清, 等. 胰管结石合并周围恶性肿瘤的危险因素分析[J]. 中华消化外科杂志, 2018, 17(12): 1204-1208. DOI: 10.3760/cma.j.issn.1673-9752.2018.12.011.
[2]	DREWES AM, BOUWENSE SAW, CAMPBELL CM, et al. Guidelines for the understanding and management of pain in chronic pancreatitis[J]. Pancreatology, 2017, 17(5): 720-731. DOI: 10.1016/j.pan.2017.07.006.
[3]	HU LH, LI ZS. Pancreatic extracorporeal shock wave lithotripsy[J]. J Hepatobiliary Surg, 2016, 24(6): 401-403. DOI: 10.3969/j.issn.1006-4761.2016.06.001. 胡良皞, 李兆申. 胰腺体外震波碎石技术[J]. 肝胆外科杂志, 2016, 24(6): 401-403. DOI: 10.3969/j.issn.1006-4761.2016.06.001.
[4]	Special Committee on Chronic Pancreatitis, Pancreatic Disease Specialized Committee, Chinese Medical Doctor Association. Guideline for the diagnosis and treatment of chronic pancreatitis(2018, Guangzhou)[J]. J Clin Hepatol, 2019, 35(1): 45-51. DOI: 10.3969/j.issn.1001-5256.2019.01.008. 中国医师协会胰腺病专业委员会慢性胰腺炎专委会. 慢性胰腺炎诊治指南(2018, 广州)[J]. 临床肝胆病杂志, 2019, 35(1): 45-51. DOI: 10.3969/j.issn.1001-5256.2019.01.008.
[5]	BASSI C, MARCHEGIANI G, DERVENIS C, et al. The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After[J]. Surgery, 2017, 161(3): 584-591. DOI: 10.1016/j.surg.2016.11.014.
[6]	WAN L, ZHAO Q, CHEN J, et al. Expert consensus on the application of pain evaluation questionnaires in China(2020)[J]. Chin J Painol, 2020, 16(3): 177-187. DOI: 10.3760/cma.j.cn101379-20190915-00075. 万丽, 赵晴, 陈军, 等. 疼痛评估量表应用的中国专家共识(2020版)[J]. 中华疼痛学杂志, 2020, 16(3): 177-187. DOI: 10.3760/cma.j.cn101379-20190915-00075.
[7]	CHEN MF, WU JS, TIAN BZ, et al. Classification and surgical management of pancreatic duct stones[J]. Chin J Dig Surg, 2010, 9(5): 348-349. DOI: 10.3760/cma.j.issn.1673-9752.2010.05.010. 陈梅福, 吴金术, 田秉障, 等. 胰管结石的分型和治疗[J]. 中华消化外科杂志, 2010, 9(5): 348-349. DOI: 10.3760/cma.j.issn.1673-9752.2010.05.010.
[8]	WANG LW, LI ZS, LI SD, et al. A multi-center survey on chronic pancreatitis in China[J]. Chin J Pancreatol, 2007, 7(1): 1-5. DOI: 10.3760/cma.j.issn.1674-1935.2007.01.001. 王洛伟, 李兆申, 李淑德, 等. 慢性胰腺炎全国多中心流行病学调查[J]. 胰腺病学, 2007, 7(1): 1-5. DOI: 10.3760/cma.j.issn.1674-1935.2007.01.001.
[9]	YOU YL, GONG JP. Diagnosis and treatment of pancreatic duct stone[J]. Int J Surg, 2021, 48(6): 405-410. DOI: 10.3760/cma.j.cn115396-20210607-00208. 游宇来, 龚建平. 胰管结石的诊疗现状[J]. 国际外科学杂志, 2021, 48(6): 405-410. DOI: 10.3760/cma.j.cn115396-20210607-00208.
[10]	ISSA Y, BRUNO MJ, BAKKER OJ, et al. Treatment options for chronic pancreatitis[J]. Nat Rev Gastroenterol Hepatol, 2014, 11(9): 556-564. DOI: 10.1038/nrgastro.2014.74.
[11]	AN DJ, AN L, ZHANG C, et al. Clinical analysis of 76 cases of chronic pancreatitis complicated with pancreatic duct stones. [J]. Chin J Pancreatol, 2018, 18(4): 267-270. DOI: 10.3760/cma.j.issn.1674-1935.2018.04.014. 安东均, 安琳, 张成, 等. 慢性胰腺炎胰管结石76例临床分析[J]. 中华胰腺病杂志, 2018, 18(4): 267-270. DOI: 10.3760/cma.j.issn.1674-1935.2018.04.014.
[12]	ERCP Group, Chinese Society of Digestive Endoscopology, Biliopancreatic Group, Chinese Association of Gastroenterologist and Hepatologis, National Clinical Research Centerfor Digestive Diseases. Chinese Guidelines for ERCP(2018)[J]. J Clin Hepatol, 2018, 34(12): 2537-2554. DOI: 10.3969/j.issn.1001-5256.2018.12.009. 中华医学会消化内镜学分会ERCP学组, 中国医师协会消化医师分会胆胰学组, 国家消化系统疾病临床医学研究中心. 中国经内镜逆行胰胆管造影术指南(2018版)[J]. 临床肝胆病杂志, 2018, 34(12): 2537-2554. DOI: 10.3969/j.issn.1001-5256.2018.12.009.
[13]	RÖSCH T, DANIEL S, SCHOLZ M, et al. Endoscopic treatment of chronic pancreatitis: a multicenter study of 1000 patients with long-term follow-up[J]. Endoscopy, 2002, 34(10): 765-771. DOI: 10.1055/s-2002-34256.
[14]	YIN ZY, LIU Q, LI XM, et al. Endoscopic retrograde cholangio-pancreatography for pancreatic duct stones[J/CD]. Chin J Hepat Surg(Electronic Edition), 2020, 9(5): 466-470. DOI: 10.3877/cma.j.issn.2095-3232.2020.05.016. 尹振宇, 刘乾, 李晓梅, 等. ERCP治疗胰管结石[J/CD]. 中华肝脏外科手术学电子杂志, 2020, 9(5): 466-470. DOI: 10.3877/cma.j.issn.2095-3232.2020.05.016.
[15]	HE X, YOU J, JIN X, et al. Rational selection of surgical treatment for pancreatic duct stones[J]. J Clin Surg, 2018, 26(7): 29-30. DOI: 10.3969/j.issn.1005-6483.2018.07.017. 何鑫, 游建, 金鑫, 等. 胰管结石外科治疗体会[J]. 临床外科杂志, 2018, 26(7): 29-30. DOI: 10.3969/j.issn.1005-6483.2018.07.017.
[16]	GU F, CHENG R, ZHANG ST. Use of ERCP combined with ESWL in the treatment of pancreatic duct stones[J]. Chin J Bases Clin Gen Surg, 2022, 29(2): 141-145. DOI: 10.7507/1007-9424.202201009. 谷丰, 程芮, 张澍田. ERCP联合ESWL在胰管结石治疗中的应用[J]. 中国普外基础与临床杂志, 2022, 29(2): 141-145. DOI: 10.7507/1007-9424.202201009.

Relative Articles

[1]	Zexin HU, Jiaqing LI, Wanci LI, Binyan ZHONG, Shuai ZHANG, Jian SHEN, Xiaoli ZHU. Efficacy and safety of transcatheter arterial chemoembolization combined with targeted therapy and immunotherapy in treatment of patients with stage Ⅱ‍b/Ⅲ‍a hepatocellular carcinoma based on China Liver Cancer Staging[J]. Journal of Clinical Hepatology, 2024, 40(3): 550-555. doi: 10.12449/JCH240318
[2]	Qiuju PENG, Tao DAI, Guibo XIE, Jinjun CHEN, Xiao CHENG, Yuan YAN. Research advances in transcatheter arterial chemoembolization combined with targeted agents or anti-PD-1/PD-L1 monoclonal antibody in treatment of patients with unresectable hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(7): 1740-1746. doi: 10.3969/j.issn.1001-5256.2023.07.033
[3]	Bailu CAO, Min AI, Ping HUANG, Yongfeng YANG. Research advances in local treatment combined with systemic therapy for advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(8): 1972-1976. doi: 10.3969/j.issn.1001-5256.2023.08.031
[4]	Jing LUO, Caihong LYU, Yongping YANG. Clinical efficacy and safety of percutaneous cryoablation combined with percutaneous ethanol injection in elderly patients with hepatocellular carcinoma aged 70 years or older[J]. Journal of Clinical Hepatology, 2022, 38(2): 365-371. doi: 10.3969/j.issn.1001-5256.2022.02.021
[5]	Jun LING, Wenwu WAN, Zheng ZENG, Huihua YAO, Ou JIANG, Bing DING. Clinical effect of transcatheter arterial chemoembolization combined with microwave ablation versus repeat resection in treatment of recurrent hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(9): 2053-2060. doi: 10.3969/j.issn.1001-5256.2022.09.020
[6]	Yihan YANG, Wanci LI, Binyan ZHONG, Jian SHEN, Xiaoli ZHU. Efficacy and safety of transarterial chemoembolization combined with camrelizumab and apatinib in treatment of advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(12): 2755-2760. doi: 10.3969/j.issn.1001-5256.2022.12.014
[7]	Xiaomin LIU, Wei SUN, Jianying WEI, Wendong LI, Xiaoyan DING, Minghua YU, Jinglong CHEN. Efficacy and safety of lenvatinib in patients with unresectable hepatocellular carcinoma previously treated with tyrosine kinase inhibitor[J]. Journal of Clinical Hepatology, 2022, 38(6): 1323-1327. doi: 10.3969/j.issn.1001-5256.2022.06.020
[8]	Xiaopeng DING, Jun TIE, Jiahao YU, Pengwei REN, Guoyun XUAN, Shuoyi MA, Changcun GUO, Ying HAN, Xinmin ZHOU. Efficacy and safety of programmed death-1 inhibitor combined with transarterial chemoembolization and anti-angiogenic drugs in treatment of advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(5): 1086-1091. doi: 10.3969/j.issn.1001-5256.2022.05.021
[9]	Chunxia PING, Jing ZHANG, Wei ZHAO, Liang MA, Da FANG, Shichang CUI. Three-year follow-up outcomes of hepatocellular carcinoma patients undergoing liver resection versus liver transplantation[J]. Journal of Clinical Hepatology, 2021, 37(2): 343-347. doi: 10.3969/j.issn.1001-5256.2021.02.019
[10]	Yanmei ZOU, Xianglin YUAN. Application value of immunotherapy in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(8): 1758-1760. doi: 10.3969/j.issn.1001-5256.2021.08.004
[11]	Ningning ZHANG, Wei LU. Targeted therapy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(8): 1753-1757. doi: 10.3969/j.issn.1001-5256.2021.08.003
[12]	Zhiyuan YU, Shiyu YANG, Jiaqi LI, Yan SUN. Current developmental status of non-surgical treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(5): 1205-1207. doi: 10.3969/j.issn.1001-5256.2021.05.048
[13]	Yisheng PENG, Pan HE, Gang ZHU, Xinkai LI, Shunde TAN, Jianfei CHEN, Jun FAN, Bin LUO, Song SU, Bo LI, Xiaoli YANG. Efficacy and safety of CalliSpheres microsphere versus conventional transcatheter arterial chemoembolization in treatment of hepatocellular carcinoma: A Meta-analysis[J]. Journal of Clinical Hepatology, 2021, 37(8): 1841-1847. doi: 10.3969/j.issn.1001-5256.2021.08.019
[14]	Lu Jian, Zhu HaiDong, Teng GaoJun, Wang Zhi. Role of interventional therapy in the downstaging of advanced liver cancer[J]. Journal of Clinical Hepatology, 2020, 36(2): 272-276. doi: 10.3969/j.issn.1001-5256.2020.02.006
[15]	Tang JinQuan, He Pan, Su Song, Luo Bin, Fang Cheng, Li Bo, Xia XianMing, Li YuWei. Short-and long-term effects of radiofrequency ablation versus minimally invasive hepatectomy in treatment of small hepatocellular carcinoma: A Meta-analysis[J]. Journal of Clinical Hepatology, 2020, 36(2): 358-362. doi: 10.3969/j.issn.1001-5256.2020.02.025
[16]	Xing AiLi, Zheng JiaSheng. Clinical effect of transcatheter arterial chemoembolization combined with local thermal ablation in treatment of large hepatocellular carcinoma and related influencing factors[J]. Journal of Clinical Hepatology, 2019, 35(1): 98-103. doi: 10.3969/j.issn.1001-5256.2019.01.018
[17]	Liang HongYuan, Guo QiYong, Mao XiaoNan, Sun Wei, Zhao Gang, Wang XiHai, Liu Zhen, Wen Feng, Lu ZaiMing. Clinical effect of sequential therapy with transarterial chemoembolization and bipolar-needle radiofrequency ablation in treatment of hepatocellular carcinoma in high-risk locations[J]. Journal of Clinical Hepatology, 2018, 34(7): 1462-1469. doi: 10.3969/j.issn.1001-5256.2018.07.020
[18]	Wang HuaMing. The interventional treatment for hepatocellular carcinoma originating from the caudate lobe[J]. Journal of Clinical Hepatology, 2016, 32(1): 68-71. doi: 10.3969/j.issn.1001-5256.2016.01.010
[19]	Sun Wei, Ding XiaoYan, Chen JingLong. Clinical effect and safety of percutaneous radiofrequency ablation following transcatheter arterial chemoembolization in treatment of primary liver cancer in high-risk locations[J]. Journal of Clinical Hepatology, 2016, 32(12): 2337-2341. doi: 10.3969/j.issn.1001-5256.2016.12.021
[20]	Zhu XiaoLi, Shen Jian. Application of local ablative therapies for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(1): 56-61. doi: 10.3969/j.issn.1001-5256.2016.01.008

Supplements(0)

Cited By

Cited by

Periodical cited type(6)

1.	杨晨，余上海，徐飞鹏，张华. 磁共振质子密度脂肪分数（MRI-PDFF）在肝脂肪定量中的应用. 临床肝胆病杂志. 2024(03): 600-605 . 本站查看
2.	刘建宪，王振松，王鑫，田宁，陈鹏，于丹，杨燕兴，程传力，邹超，甘洁. 基于5.0T MRI定量肝脏质子密度脂肪分数. 中国医学影像技术. 2024(05): 671-676 .
3.	贺小红，洪居陆，高明勇，吴李贤，杨镜全. 两种场强磁共振IDEAL-IQ序列对质子密度脂肪分数和铁含量定量分析的初步对比研究. 国际放射医学核医学杂志. 2023(03): 148-154 .
4.	宋玥锦，王凯，牛宏伟，王春生. 影像学检查方法在非酒精性脂肪性肝病定量分析中的应用. 影像技术. 2023(03): 69-74 .
5.	栗雯霏，张捷，栗建辉. 影像技术对非酒精性脂肪肝的评价. 肝脏. 2023(07): 875-880 .
6.	黄江水，文建荣，宋国军，蒋小龙，李伟，王敏，唐艳芬. MRI-PDFF降低对非酒精性脂肪性肝病患者肝纤维化预测研究. 影像研究与医学应用. 2022(23): 69-71 .

Other cited types(3)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(5)

Get Citation

PDF

XML

Article Metrics

Article views (488) PDF downloads(78)

Selection of treatment regimens for pancreatic duct stones: A comparative analysis

DOI: 10.3969/j.issn.1001-5256.2022.11.023

Abstract

References

Relative Articles

Cited by

Periodical cited type(6)

Other cited types(3)

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content